Humanized Anti-TL1A Antibodies for IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel disease (IBD) are inadequate, particularly for severe forms characterized by intestinal fibrosis, with limited targeted therapeutic options available, leading to ineffective treatments and the need for invasive surgical interventions that come with significant risks.
Innovation Solution
Development of tumor necrosis factor ligand 1A (TL1A) binding antibodies with specific structural features, such as low immunogenicity and high monomeric fraction, to target IBD pathogenesis, including severe forms with intestinal fibrosis, using antibodies with modified human frameworks and high expression levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-inflammatory therapies are used for IBD treatment, then patients receive standard care, but the therapies are ineffective for severe forms and lead to disease worsening
Solution Approach 1:
The patent applies parameter changes by modifying the molecular structure of antibodies through specific amino acid substitutions in the framework regions (e.g., positions 47, 45, 55, 78, 80, 82, 89, 91 in heavy chain variable region). These structural parameter changes create antibodies with optimized properties including reduced immunogenicity, enhanced stability, and improved binding affinity to TL1A, thereby achieving reliable treatment effectiveness for severe IBD forms where existing therapies fail
Solution Approach 2:
The patent implements local quality by introducing specific amino acid modifications at particular positions within the antibody framework regions while leaving other regions unchanged. For example, specific substitutions at positions 47, 45, and 55 in the heavy chain variable framework region create localized improvements in antibody properties such as reduced immunogenicity and enhanced stability, allowing the antibody to maintain high affinity for TL1A while improving overall therapeutic performance
2Reliability
If invasive surgical interventions are performed for IBD, then structural plasty or resection is achieved, but post-operative risks increase
Solution Approach 1:
The patent replaces the mechanical surgical intervention system with a biochemical therapy system. Instead of performing structural plasty or resection surgery to treat severe IBD forms, the invention uses engineered TL1A-binding antibodies that specifically target and block the TL1A pathway involved in fibrosis and inflammation. This substitution eliminates surgical risks such as anastomotic leak, infection, and bleeding while providing effective treatment for intestinal fibrosis through molecular-level intervention
3Object-affected harmful factors
If humanized antibodies are developed with modified frameworks, then immunogenicity is reduced, but manufacturing complexity increases
Solution Approach 1:
The patent systematically changes the structural parameters of the antibody framework by introducing specific amino acid substitutions at defined positions (47, 45, 55, 78, 80, 82, 89, 91 in heavy chain variable region and 54, 55 in light chain variable region). These controlled parameter changes reduce immunogenicity by making the antibody more human-like while maintaining binding function, and the systematic nature of these changes actually simplifies manufacturing by providing clear design rules rather than increasing complexity
Data Source
AI summary
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).